@hemehub.bsky.social
HemeHub (formerly BMFCases) | Supporting hematology by enhancing care, driving innovation, and advancing research & treatment strategies.
https://www.hemehub.org
https://www.hemehub.org
Happening this Friday!
🔗Register now: hemehub.org/live-events
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #BloodDisorders @jthjournal.bsky.social @isth.org @htrstoday.bsky.social @thjournal.bsky.social @sfthemostase.bsky.social
🔗Register now: hemehub.org/live-events
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #BloodDisorders @jthjournal.bsky.social @isth.org @htrstoday.bsky.social @thjournal.bsky.social @sfthemostase.bsky.social
🩸Join us for a special session with Dr. Shannon Meeks to explore advances in hemophilia A research!
🔗Register now: hemehub.org/live-events
#HemophiliaA #Hemostasis #BloodDisorders #Hematology #ClinicalTrials @isth.org @thjournal.bsky.social @ash.edu.hematology.org @cuhemeonc.bsky.social
🔗Register now: hemehub.org/live-events
#HemophiliaA #Hemostasis #BloodDisorders #Hematology #ClinicalTrials @isth.org @thjournal.bsky.social @ash.edu.hematology.org @cuhemeonc.bsky.social
November 10, 2025 at 9:53 PM
Today’s question focuses on bleed management in a young patient with severe Hemophilia A who has developed an inhibitor.
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #BloodDisorders
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #BloodDisorders
November 10, 2025 at 9:51 PM
Today’s question focuses on bleed management in a young patient with severe Hemophilia A who has developed an inhibitor.
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #BloodDisorders
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #BloodDisorders
Facts about Hemophilia A: Molecular Genetics and Pathogenesis
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy @ash.edu.hematology.org @ash.hematology.org @htrstoday.bsky.social @thjournal.bsky.social @athnnews.bsky.social @isth.org @jthjournal.bsky.social
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy @ash.edu.hematology.org @ash.hematology.org @htrstoday.bsky.social @thjournal.bsky.social @athnnews.bsky.social @isth.org @jthjournal.bsky.social
November 10, 2025 at 9:49 PM
Facts about Hemophilia A: Molecular Genetics and Pathogenesis
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy @ash.edu.hematology.org @ash.hematology.org @htrstoday.bsky.social @thjournal.bsky.social @athnnews.bsky.social @isth.org @jthjournal.bsky.social
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy @ash.edu.hematology.org @ash.hematology.org @htrstoday.bsky.social @thjournal.bsky.social @athnnews.bsky.social @isth.org @jthjournal.bsky.social
Today’s question highlights how to approach a new bleed and prolonged aPTT in a patient on prophylaxis for Hemophilia A.
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #BloodDisorders
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #BloodDisorders
November 8, 2025 at 10:36 PM
Today’s question highlights how to approach a new bleed and prolonged aPTT in a patient on prophylaxis for Hemophilia A.
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #BloodDisorders
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #BloodDisorders
Facts about Hemophilia A: Molecular Genetics and Pathogenesis
Key genetic mutations in the factor 8 gene determine disease severity, with intron inversions linked to severe cases and missense mutations causing milder forms.
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation
Key genetic mutations in the factor 8 gene determine disease severity, with intron inversions linked to severe cases and missense mutations causing milder forms.
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation
November 8, 2025 at 10:35 PM
Facts about Hemophilia A: Molecular Genetics and Pathogenesis
Key genetic mutations in the factor 8 gene determine disease severity, with intron inversions linked to severe cases and missense mutations causing milder forms.
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation
Key genetic mutations in the factor 8 gene determine disease severity, with intron inversions linked to severe cases and missense mutations causing milder forms.
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation
🧬 Today’s question focuses on prophylactic options for a young patient with severe Hemophilia A and considerations for administration route.
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #InternalMedicine #ClinicalTrials
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #InternalMedicine #ClinicalTrials
November 6, 2025 at 9:46 PM
🧬 Today’s question focuses on prophylactic options for a young patient with severe Hemophilia A and considerations for administration route.
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #InternalMedicine #ClinicalTrials
See the answer and explanation on the next slide!
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation #InternalMedicine #ClinicalTrials
Facts about Hemophilia A: Disease Overview and Epidemiology
Advances in screening, data reporting, and prophylaxis have transformed outcomes in high-income countries, while access gaps persist in resource-limited countries.
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation
Advances in screening, data reporting, and prophylaxis have transformed outcomes in high-income countries, while access gaps persist in resource-limited countries.
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation
November 6, 2025 at 9:44 PM
Facts about Hemophilia A: Disease Overview and Epidemiology
Advances in screening, data reporting, and prophylaxis have transformed outcomes in high-income countries, while access gaps persist in resource-limited countries.
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation
Advances in screening, data reporting, and prophylaxis have transformed outcomes in high-income countries, while access gaps persist in resource-limited countries.
#Hemophilia #BleedingDisorders #Hematology #RareDiseases #Coagulation
Happening this Friday!
🔗Register now: hemehub.org/live-events
#SickleCellDisease #Hematology #CellTherapy #RareDiseases #BloodDisorders @asgct.bsky.social @cfgtedinburgh.bsky.social @genesndiseases.bsky.social
@sicklecell101.bsky.social @ascaa.bsky.social @sicklecelluk.bsky.social
🔗Register now: hemehub.org/live-events
#SickleCellDisease #Hematology #CellTherapy #RareDiseases #BloodDisorders @asgct.bsky.social @cfgtedinburgh.bsky.social @genesndiseases.bsky.social
@sicklecell101.bsky.social @ascaa.bsky.social @sicklecelluk.bsky.social
🩸Join us for an exclusive webinar with Dr. Thomas Coates, focusing on advances in the management of sickle cell disease, vascular complications, and transfusion-related iron overload.
Register now: hemehub.org/live-events
#Hematology #SickleCellDisease #BloodDisorders #MedicalEducation
Register now: hemehub.org/live-events
#Hematology #SickleCellDisease #BloodDisorders #MedicalEducation
November 6, 2025 at 1:18 AM
🧬Today's question examines how coagulation studies help differentiate causes of prolonged aPTT in a child with recurrent bleeding.
See the answer and explanation on the next slide!
#HemophiliaA #FactorVIII #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #InternalMedicine
See the answer and explanation on the next slide!
#HemophiliaA #FactorVIII #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #InternalMedicine
November 6, 2025 at 1:12 AM
🧬Today's question examines how coagulation studies help differentiate causes of prolonged aPTT in a child with recurrent bleeding.
See the answer and explanation on the next slide!
#HemophiliaA #FactorVIII #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #InternalMedicine
See the answer and explanation on the next slide!
#HemophiliaA #FactorVIII #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #InternalMedicine
Facts about Hemophilia A:
A concise overview of the mechanisms that link F8 gene mutations to clinical phenotype and disease severity.
#HemophiliaA #FactorVIII #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #TranslationalMedicine #BloodDisorders
A concise overview of the mechanisms that link F8 gene mutations to clinical phenotype and disease severity.
#HemophiliaA #FactorVIII #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #TranslationalMedicine #BloodDisorders
November 6, 2025 at 1:11 AM
Facts about Hemophilia A:
A concise overview of the mechanisms that link F8 gene mutations to clinical phenotype and disease severity.
#HemophiliaA #FactorVIII #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #TranslationalMedicine #BloodDisorders
A concise overview of the mechanisms that link F8 gene mutations to clinical phenotype and disease severity.
#HemophiliaA #FactorVIII #BleedingDisorders #Hematology #RareDiseases #Coagulation #GeneTherapy #ClinicalTrials #TranslationalMedicine #BloodDisorders
🩸This Month on HemeHub: Hemophilia A
Join us as we explore advances in the understanding and management of Hemophilia A, including strategies to improve patient outcomes and care. Stay tuned for our upcoming session featuring Dr. Shannon Meeks!
#HemophiliaA #Hematology #RareDiseases
Join us as we explore advances in the understanding and management of Hemophilia A, including strategies to improve patient outcomes and care. Stay tuned for our upcoming session featuring Dr. Shannon Meeks!
#HemophiliaA #Hematology #RareDiseases
November 5, 2025 at 12:41 AM
🩸This Month on HemeHub: Hemophilia A
Join us as we explore advances in the understanding and management of Hemophilia A, including strategies to improve patient outcomes and care. Stay tuned for our upcoming session featuring Dr. Shannon Meeks!
#HemophiliaA #Hematology #RareDiseases
Join us as we explore advances in the understanding and management of Hemophilia A, including strategies to improve patient outcomes and care. Stay tuned for our upcoming session featuring Dr. Shannon Meeks!
#HemophiliaA #Hematology #RareDiseases
🧬The second question of the day focuses on how patient-reported outcomes reflect clinical benefit after Casgevy therapy.
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders
October 29, 2025 at 7:03 PM
🧬The second question of the day focuses on how patient-reported outcomes reflect clinical benefit after Casgevy therapy.
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders
🧬 Today’s first question focuses on interpreting hemoglobin expression patterns following Casgevy treatment.
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases
October 29, 2025 at 7:02 PM
🧬 Today’s first question focuses on interpreting hemoglobin expression patterns following Casgevy treatment.
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases
General Facts about Gene Therapy:
#LentiGlobin and #Exa-cel studies
#Casgevy #Lyfgenia #GeneTherapy #CRISPR #SickleCellDisease #Hematology #CellTherapy #ClinicalTrials
@ash.edu.hematology.org @asgct.bsky.social @cfgtedinburgh.bsky.social @genesndiseases.bsky.social
@bsochaem.bsky.social
#LentiGlobin and #Exa-cel studies
#Casgevy #Lyfgenia #GeneTherapy #CRISPR #SickleCellDisease #Hematology #CellTherapy #ClinicalTrials
@ash.edu.hematology.org @asgct.bsky.social @cfgtedinburgh.bsky.social @genesndiseases.bsky.social
@bsochaem.bsky.social
October 29, 2025 at 7:01 PM
General Facts about Gene Therapy:
#LentiGlobin and #Exa-cel studies
#Casgevy #Lyfgenia #GeneTherapy #CRISPR #SickleCellDisease #Hematology #CellTherapy #ClinicalTrials
@ash.edu.hematology.org @asgct.bsky.social @cfgtedinburgh.bsky.social @genesndiseases.bsky.social
@bsochaem.bsky.social
#LentiGlobin and #Exa-cel studies
#Casgevy #Lyfgenia #GeneTherapy #CRISPR #SickleCellDisease #Hematology #CellTherapy #ClinicalTrials
@ash.edu.hematology.org @asgct.bsky.social @cfgtedinburgh.bsky.social @genesndiseases.bsky.social
@bsochaem.bsky.social
🩸Join us for a special session with Dr. Shannon Meeks to explore advances in hemophilia A research!
🔗Register now: hemehub.org/live-events
#HemophiliaA #Hemostasis #BloodDisorders #Hematology #ClinicalTrials @isth.org @thjournal.bsky.social @ash.edu.hematology.org @cuhemeonc.bsky.social
🔗Register now: hemehub.org/live-events
#HemophiliaA #Hemostasis #BloodDisorders #Hematology #ClinicalTrials @isth.org @thjournal.bsky.social @ash.edu.hematology.org @cuhemeonc.bsky.social
October 29, 2025 at 12:09 AM
🩸Join us for a special session with Dr. Shannon Meeks to explore advances in hemophilia A research!
🔗Register now: hemehub.org/live-events
#HemophiliaA #Hemostasis #BloodDisorders #Hematology #ClinicalTrials @isth.org @thjournal.bsky.social @ash.edu.hematology.org @cuhemeonc.bsky.social
🔗Register now: hemehub.org/live-events
#HemophiliaA #Hemostasis #BloodDisorders #Hematology #ClinicalTrials @isth.org @thjournal.bsky.social @ash.edu.hematology.org @cuhemeonc.bsky.social
🧬 Today's second question highlights the significance of neutrophil engraftment timing in #Casgevy studies.
See the answer and explanation on the next slide!
#GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders #StemCells
See the answer and explanation on the next slide!
#GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders #StemCells
October 28, 2025 at 11:59 PM
🧬 Today's second question highlights the significance of neutrophil engraftment timing in #Casgevy studies.
See the answer and explanation on the next slide!
#GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders #StemCells
See the answer and explanation on the next slide!
#GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders #StemCells
🧬 Today's first question focuses on the safety profile of #Casgevy, examining which adverse events have not been reported in clinical trials to date.
See the answer and explanation on the next slide!
#GeneTherapy #SickleCellDisease #Hematology #CellTherapy #RareDiseases #ClinicalTrials
See the answer and explanation on the next slide!
#GeneTherapy #SickleCellDisease #Hematology #CellTherapy #RareDiseases #ClinicalTrials
October 28, 2025 at 11:58 PM
🧬 Today's first question focuses on the safety profile of #Casgevy, examining which adverse events have not been reported in clinical trials to date.
See the answer and explanation on the next slide!
#GeneTherapy #SickleCellDisease #Hematology #CellTherapy #RareDiseases #ClinicalTrials
See the answer and explanation on the next slide!
#GeneTherapy #SickleCellDisease #Hematology #CellTherapy #RareDiseases #ClinicalTrials
🧬The second question of the day explores key predictors of lasting clinical benefit after Casgevy therapy.
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders
October 27, 2025 at 11:41 PM
🧬The second question of the day explores key predictors of lasting clinical benefit after Casgevy therapy.
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders
Today’s first question explores why some complications may persist after Casgevy therapy. See the answer and explanation on the next slide!
@ucsdmedschool.bsky.social @stanfordmedicine.bsky.social @bcmhouston.bsky.social @yaleschoolofmed.bsky.social @dukemedschool.bsky.social @dgsomucla.bsky.social
@ucsdmedschool.bsky.social @stanfordmedicine.bsky.social @bcmhouston.bsky.social @yaleschoolofmed.bsky.social @dukemedschool.bsky.social @dgsomucla.bsky.social
October 27, 2025 at 11:40 PM
Today’s first question explores why some complications may persist after Casgevy therapy. See the answer and explanation on the next slide!
@ucsdmedschool.bsky.social @stanfordmedicine.bsky.social @bcmhouston.bsky.social @yaleschoolofmed.bsky.social @dukemedschool.bsky.social @dgsomucla.bsky.social
@ucsdmedschool.bsky.social @stanfordmedicine.bsky.social @bcmhouston.bsky.social @yaleschoolofmed.bsky.social @dukemedschool.bsky.social @dgsomucla.bsky.social
Further results from the Exa-cel study.
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #BloodDisorders @ash.edu.hematology.org @asgct.bsky.social @dgsomucla.bsky.social @dukemedschool.bsky.social @harvardmed.bsky.social @yaleschoolofmed.bsky.social
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #BloodDisorders @ash.edu.hematology.org @asgct.bsky.social @dgsomucla.bsky.social @dukemedschool.bsky.social @harvardmed.bsky.social @yaleschoolofmed.bsky.social
October 27, 2025 at 11:38 PM
Further results from the Exa-cel study.
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #BloodDisorders @ash.edu.hematology.org @asgct.bsky.social @dgsomucla.bsky.social @dukemedschool.bsky.social @harvardmed.bsky.social @yaleschoolofmed.bsky.social
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #BloodDisorders @ash.edu.hematology.org @asgct.bsky.social @dgsomucla.bsky.social @dukemedschool.bsky.social @harvardmed.bsky.social @yaleschoolofmed.bsky.social
🧬 Second question of the day focuses on understanding breakthrough vaso-occlusive events in patients treated with Casgevy and what they reveal about post-therapy physiology.
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy
October 26, 2025 at 12:45 AM
🧬 Second question of the day focuses on understanding breakthrough vaso-occlusive events in patients treated with Casgevy and what they reveal about post-therapy physiology.
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy
🧬 Today’s first question highlights the importance of pancellular HbF expression after Casgevy.
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine @bsochaem.bsky.social @asgct.bsky.social @ash.hematology.org
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine @bsochaem.bsky.social @asgct.bsky.social @ash.hematology.org
October 26, 2025 at 12:44 AM
🧬 Today’s first question highlights the importance of pancellular HbF expression after Casgevy.
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine @bsochaem.bsky.social @asgct.bsky.social @ash.hematology.org
See the answer and explanation on the next slide!
#Casgevy #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine @bsochaem.bsky.social @asgct.bsky.social @ash.hematology.org
Additional results from the Exa-cel study.
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy @ash.hematology.org @asgct.bsky.social @genesndiseases.bsky.social @bsochaem.bsky.social @ash.edu.hematology.org
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy @ash.hematology.org @asgct.bsky.social @genesndiseases.bsky.social @bsochaem.bsky.social @ash.edu.hematology.org
October 26, 2025 at 12:42 AM
Additional results from the Exa-cel study.
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy @ash.hematology.org @asgct.bsky.social @genesndiseases.bsky.social @bsochaem.bsky.social @ash.edu.hematology.org
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy @ash.hematology.org @asgct.bsky.social @genesndiseases.bsky.social @bsochaem.bsky.social @ash.edu.hematology.org
Our session with Dr. Thomas Coates is in 2 weeks!
Don’t miss this opportunity to hear from a top expert in the field!
🔗Register now:
hemehub.org/live-events
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine
Don’t miss this opportunity to hear from a top expert in the field!
🔗Register now:
hemehub.org/live-events
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine
🩸Join us for an exclusive webinar with Dr. Thomas Coates, focusing on advances in the management of sickle cell disease, vascular complications, and transfusion-related iron overload.
Register now: hemehub.org/live-events
#Hematology #SickleCellDisease #BloodDisorders #MedicalEducation
Register now: hemehub.org/live-events
#Hematology #SickleCellDisease #BloodDisorders #MedicalEducation
October 22, 2025 at 10:58 PM
Our session with Dr. Thomas Coates is in 2 weeks!
Don’t miss this opportunity to hear from a top expert in the field!
🔗Register now:
hemehub.org/live-events
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine
Don’t miss this opportunity to hear from a top expert in the field!
🔗Register now:
hemehub.org/live-events
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine
Further results from the Exa-cel study.
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy #HematopoieticStemCells
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy #HematopoieticStemCells
October 22, 2025 at 10:58 PM
Further results from the Exa-cel study.
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy #HematopoieticStemCells
Focus: CLIMB SCD-121 Trial
#Casgevy #GeneTherapy #CRISPRGeneEditing #SickleCellGeneTherapy #SickleCellDisease #Hematology #CellTherapy #TranslationalMedicine #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy #HematopoieticStemCells